Gilead has long-standing patient support programs in the U.S. to help people with financial needs access Truvada for PrEP. Gilead Copay offers Copay coupon support for commercially insured individuals, through which patients can only pay $US 0 per bottle for Truvada for PrEP. Those who don`t have insurance can use Truvada for free for PrEP through our long-standing medication support program or in the near future through the new CDC-Gilead partnership. Those interested in learning more about the support programs that may be available to them are asked to visit the Gilead Advancing Access website® Site. Meanwhile, Gilead and HHS are also partners in a free drug distribution program, after Gilead struck a major donation deal last year. And as the COVID-19 pandemic unfolds, the company said it is committed to helping with that response. Gileads Remdesivir is one of the most promising candidates against COVID-19, although the latest early data for the drug has raised questions about its effectiveness. For more information about Gilead Sciences, please visit the company`s website at, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. „Under President Trump`s leadership HHS has worked with Gilead to provide preventative medications for people who might otherwise not be able to: access or afford this important treatment.

The majority of Americans who are at risk and could protect themselves with PrEP are still not getting the drug. This agreement will significantly fill this gap and deliver on President Trump`s promise to end the HIV epidemic in the United States. ” – by Caitlyn Stulpin In particular, Gilead says that the federal government applied for patent protection for the HIV prevention drug Truvada without properly notifying the company. As part of the deals, Gilead says, the company has made „significant” amounts of drugs available to federal researchers „free of charge” for studies. The government was in turn responsible for informing the company if it made any discoveries. The clinical trials deal undereded the stimulus that U.S. officials would not attempt to patent the work, according to the complaint. .

. .